Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 13/20 | 0.67 |
| ▸ | MMP13 | P45452 | 13/20 | 0.44 |
| ▸ | MMP3 | P08254 | 8/20 | 0.43 |
| ▸ | MMP10 | P09238 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 4/20 | 0.42 |
| ▸ | MMP8 | P22894 | 3/20 | 0.42 |
| ▸ | MMP14 | P50281 | 3/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6691684 | 0.92 | MMP1 (0.79) | MMP1MMP13MMP3SMN1; SMN2MMP9 | |
| SCHEMBL6813091 | 0.92 | MMP1 (0.76) | MMP1MMP13MMP3SMN1; SMN2MMP9 | |
| SCHEMBL6813262 | 0.90 | MMP1 (0.67) | MMP1MMP13MMP3MMP10SMN1; SMN2 | |
| SCHEMBL27478657 | 0.84 | MMP1 (0.75) | MMP1MMP13MMP3MMP10MMP9 | |
| SCHEMBL6992588 | 0.84 | MMP1 (0.59) | MMP1MMP13MMP3SMN1; SMN2MMP9 | |
| SCHEMBL6870777 | 0.84 | MMP1 (0.59) | MMP1MMP13MMP3SMN1; SMN2MMP9 | |
| SCHEMBL3914707 | 0.84 | MMP1 (0.63) | MMP1MMP13MMP3MMP10MMP9 | |
| SCHEMBL6693057 | 0.84 | MMP1 (0.68) | MMP1MMP13MMP3MMP9MMP8 | |
| SCHEMBL6691163 | 0.83 | MMP1 (0.65) | MMP1MMP13MMP3MMP10MMP9 | |
| SCHEMBL7347709 | 0.82 | MMP1 (0.56) | MMP1MMP13MMP3SMN1; SMN2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6417229-B1 | ENZYME INHIBITORS | PFIZER INC | 2002-07-09 | — | — | US | claimed |
| EP-1088550-A1 | alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| EP-1415984-A1 | Aryloxyarylsulfonylamino hydroxamic acid derivatives | Pfizer Products Inc. (US) | 2004-05-06 | — | — | EP | disclosed |
| EP-1003720-B1 | ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PROD INC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6417229-B1 | ENZYME INHIBITORS | PFIZER INC | 2002-07-09 | — | — | US | disclosed |
| US-6214872-B1 | ANTIARTHRITIC AND ANTICARCINOGENIC AGENTS | PFIZER INC. | 2001-04-10 | — | — | US | disclosed |
| EP-1088550-A1 | alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |